2024年WHO全球结核病报告：全球与中国关键数据分析

doi:10.19871/j.cnki.xfcrbzz.2024.06.016

新发传染病电子杂志 ›› 2024, Vol. 9 ›› Issue (6): 92-97.doi: 10.19871/j.cnki.xfcrbzz.2024.06.016

2024年WHO全球结核病报告：全球与中国关键数据分析

李媛媛¹, 谢晶晶¹, 李树涛¹, 苏东栋¹, 郑甜¹, 陆普选², 彭溢¹

1.新疆维吾尔自治区传染病医院结核科,新疆乌鲁木齐 830001;
2.深圳市慢性病防治中心影像中心,广东深圳 518020

收稿日期:2024-11-02 出版日期:2025-01-25 发布日期:2025-01-25
通讯作者: 彭溢,Email：18999918582@189.com
基金资助:
2024年度省部共建中亚高发病成因与防治国家重点实验室联合基金项目（SKL-HIDCA-2024-BF2）

2024 WHO Tuberculosis Report: key data analysis for China and the global world

Li Yuanyuan¹, Xie Jingjing¹, Li Shutao¹, Su Dongdong¹, Zheng Tian¹, Lu Puxuan², Peng Yi¹

1. Department of Tuberculosis, Xinjiang Uyghur Autonomous Region Infectious Disease Hospital, Xinjiang Urumqi 830001, China;
2. Department of Radiology, Shenzhen Center for Chronic Disease Control, Guangdong Shenzhen 518020, China

Received:2024-11-02 Online:2025-01-25 Published:2025-01-25

摘要/Abstract

摘要： 据WHO估算,2023年全球新增结核病患者1080万例;中国新增病例数为74.1万例（占全球发病数的6.8%）,在30个结核病高负担国家中排第3位。全球结核病死亡人数约125万例,中国结核病死亡数估算为2.7万例。2023年,全球有约40万例耐多药/利福平耐药结核病患者,中国约有2.9万例。2015–2023年结核病发病率累计下降8.3%,死亡人数净减少23%,但仍有约50%的结核病患者及其家庭面临灾难性支出,与WHO终止结核病策略所确定的2025年阶段性目标存在较大差距。2023年全球结核病诊治服务进一步复苏,全球新诊断并报告结核病患者820万例,为1995年WHO监测全球结核病数据以来的最高值,然而通报数与估算数之间仍然存在约270万例的差距。在全球结核病负担不断上升的背景下,加强资源投入和多方合作已刻不容缓。WHO呼吁各国加大结核病防治力度,以应对这一日益严峻的全球健康威胁。对标全球数据,中国在结核病防治方面取得了一定进展,治疗成功率较高且覆盖范围广泛。但中国在耐药性结核病监控、经济支持和预防性治疗方面与全球目标仍有较大差距。未来需要政府和社会各界共同努力,持续加大投入和防控力度,以实现“2035年终结结核病”的战略目标。

关键词: 结核病, 报告, 终止结核病策略, 数据分析

Abstract: It is estimated that in 2023, there were 10.8 million new cases of tuberculosis globally, with China recording 741 000 new cases (accounting for 6.8% of the global incidence rate), ranking third among the 30 high-burden countries for tuberculosis. The global death toll from tuberculosis was approximately 1.25 million, with an estimated 27 000 deaths in China. In 2023, there were about 400 000 cases of multi-drug resistant/rifampin-resistant tuberculosis globally, with approximately 29 000 cases in China. From 2015 to 2023, the incidence rate of tuberculosis decreased by 8.3%, and the net decrease in deaths was 23%. However, about 50% of tuberculosis patients and their families still face catastrophic expenses, which is far from the 2025 milestone set by the World Health Organization's End TB Strategy. In 2023, global tuberculosis diagnosis and treatment services further recovered, with 8.2 million new cases of tuberculosis diagnosed and reported globally, the highest since the WHO began monitoring global tuberculosis data in 1995. However, there is still a gap of approximately 2.7 million cases between the reported and estimated numbers. Against the backdrop of a rising global tuberculosis burden, it is urgent to strengthen resource investment and multi-party cooperation. The WHO calls on countries to increase their efforts in tuberculosis prevention and control to address this increasingly severe global health threat. Compared to global data, China has made certain progress in tuberculosis prevention and control, with a relatively high treatment success rate and wide coverage. However, China still has a significant gap with global goals in terms of drug resistance monitoring, economic support, and preventive treatment. In the future, it will require joint efforts from the government and all sectors of society to continuously increase investment and prevention and control efforts to achieve the strategic goal of "ending tuberculosis".

Key words: Tuberculosis, Report, The end tuberculosis strategy, Data analysis

中图分类号:

李媛媛, 谢晶晶, 李树涛, 苏东栋, 郑甜, 陆普选, 彭溢. 2024年WHO全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2024, 9(6): 92-97.

Li Yuanyuan, Xie Jingjing, Li Shutao, Su Dongdong, Zheng Tian, Lu Puxuan, Peng Yi. 2024 WHO Tuberculosis Report: key data analysis for China and the global world[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(6): 92-97.

参考文献

[1] WORLD HEALTH ORGANIZATION. Global tuberculosis report2024[EB/OL]. [2024-10-29]. https://www.who.int/publications/i/item/9789240101531.
[2] 卢春容, 谭卫国, 陆普选, 等. 2023年who全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2023, 8(6): 73-78.
[3] 宋敏, 陆普选, 方伟军, 等. 2022年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2022, 8(1): 87-92.
[4] WORLD HEALTH ORGANIZATION. Global tuberculosis report2023[EB/OL]. [2024-11-07]. https://www.who.int/publications/i/item/9789240083851.
[5] WORLD HEALTH ORGANIZATION. Global tuberculosis report2022[EB/OL]. [2022-10-27]. https://www.who.int/publications/i/item/9789240061729.
[6] WORLD HEALTH ORGANIZATION. Global tuberculosis report2021[EB/OL]. [2021-10-14]. https://www.who.int/publications/i/item/9789240037021.
[7] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities[EB/OL]. [2024-04-29].https://www.who.int/publications/i/item/9789240087002.
[8] WORLD HEALTH ORGANIZATION.The end TB strategy[EB/OL]. [2015-08-16].https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19.
[9] WORLD HEALTH ORGANIZATION. Status update: reaching the targets in the political declaration of the united nations general assembly high-level meeting on the fight against tuberculosis, september2023[EB/OL]. [2023-09-15]. https://www.who.int/publications/m/item/WHO-UCN-TB-2023.4.
[10] WORLD HEALTH ORGANIZATION.UN general assembly high-level meeting on the fight against tuberculosis, 2023[EB/OL]. [2023-09-22]. https://www.who.int/activities/preparing-for-the-un-high-level-meeting-on-the-fight-against-tuberculosis--2023.
[11] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment[EB/OL]. [2020-02-25].https://www.who.int/publications/i/item/9789240001503.
[12] LESTARI T, FUADY A, YANI FF, et al.The Development Of The National Tuberculosis Research Priority In Indonesia: A Comprehensive Mixed-Method Approach[J]. PLoS One, 2023,18(2):E0281591.
[13] ISKANDAR D, SUWANTIKA AA, PRADIPTA IS, et al.Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19[J]. Lancet Glob Health, 2023, 11(1):e117-e125.
[14] WORLD HEALTH ORGANIZATION.Diagnosis of tuberculosis and detection of drug-resistance: meeting report, geneva, switzerland, 6-10 may 2024[M]. World Health Organization, 2024.
[15] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update[EB/OL]. [2022-12-15]. https://www.who.int/publications/i/item/9789240063129.
[16] WORLD HEALTH ORGANIZATION.Key updates to the treatment of drug-resistant tuberculosis: rapid communication, june 2024[M]. World Health Organization, 2024.
[17] 李军丽, 郭晓楠, 梁艳, 等. 结核病疫苗研究进展与突破[J]. 中国防痨杂志, 2024, 46(10):1171-1184.

2024年WHO全球结核病报告：全球与中国关键数据分析

2024 WHO Tuberculosis Report: key data analysis for China and the global world

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	段晓菲, 吴桂辉, 杨洁, 蒋良双. 2012–2022年成都市肺结核流行特征与治疗转归分析[J]. 新发传染病电子杂志, 2024, 9(5): 19-24.
[2]	朱庆东, 王琦, 宋畅, 赵春艳, 阳世雄. 高通量测序技术在结核病诊断和耐药检测中的应用进展[J]. 新发传染病电子杂志, 2024, 9(5): 78-82.
[3]	刘钰, 孙小琴, 刘婷, 徐亚丽, 虎维东. 肺部、肠道菌群与结核病发生发展的研究进展[J]. 新发传染病电子杂志, 2024, 9(4): 61-67.
[4]	王晓霞, 谭守勇, 黄绍梅, 胡海霞. 80例儿童中枢神经系统结核病临床特征分析[J]. 新发传染病电子杂志, 2024, 9(1): 37-41.
[5]	卢春容, 谭卫国, 陆普选, 王豪朋. 2023年WHO全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2023, 8(6): 73-78.
[6]	任国利, 赵俊鹏, 秦莉, 邸宝春, 田杰, 莫明华, 李国刚. 国内结核病临床实验室检验技术效度荟萃分析[J]. 新发传染病电子杂志, 2023, 8(5): 16-24.
[7]	巫雪琴, 程耀, 杨铭, 袁平, 李娇, 孙秋萍. 耐多药结核病患者治疗成功因素分析与预测模型的建立[J]. 新发传染病电子杂志, 2023, 8(4): 30-35.
[8]	吴多池, 梁爱群, 吴烨莹, 云飞. 结核菌素皮肤试验、干扰素释放酶联免疫法及核酸分子检测技术在结核病中的诊断价值[J]. 新发传染病电子杂志, 2023, 8(4): 60-63.
[9]	谢东胜, 邓国防, 韩婷婷. 先天性结核病的诊治进展[J]. 新发传染病电子杂志, 2023, 8(3): 74-78.
[10]	徐新月, 赵晓龙. 结核病与糖尿病共病的药物治疗进展[J]. 新发传染病电子杂志, 2023, 8(2): 74-77.
[11]	徐园红, 吴张君, 罗槑, 朱玛, 王冬梅, 曾沛斌. 四川地区儿童分枝杆菌感染及耐药情况分析[J]. 新发传染病电子杂志, 2023, 8(1): 39-43.
[12]	钟倩红, 赵之梦, 杜芳芳, 成诗明, 周杰, 黄飞, 叶一农, 张锡林, 钟球. 佛山市利福平耐药肺结核患者医疗费用现状调查[J]. 新发传染病电子杂志, 2023, 8(1): 66-70.
[13]	宋敏, 陆普选, 方伟军, 韩远远, 梁瑞云. 2022年WHO全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2023, 8(1): 87-92.
[14]	李敏璐, 廖金生, 刘靖元, 邱永宏, 郑铁洪. 深圳市某中学一起肺结核疫情的分子流行病学和防控研究[J]. 新发传染病电子杂志, 2022, 7(4): 42-46.
[15]	刘霞, 蔡琳. 艾滋病合并噬血细胞综合征3例报道并文献复习[J]. 新发传染病电子杂志, 2022, 7(4): 70-73.